Biểu đồ giá cổ phiếu MIRM
MIRM Giá
Mirum Pharmaceuticals Inc
$102.93
-6.49%
$-7.14
Khi đóng cửa: May 07, 16:00:00 GMT-4
$102.43
-0.48%
$-0.5
Phiên trước giờ: May 08, 06:10:39 GMT-4
Quay lại
Mirum Pharmaceuticals Inc (MIRM) Giá
Thống kê chính
Giá đóng cửa trước
$110.08
Giá mở cửa
$109.62
Phạm vi ngày
$98.59 - $112
Phạm vi 52 tuần
$40 - $109.28
Khối lượng
1.9M
Khối lượng trung bình
827.3K
Tỷ suất cổ tức
--
EPS (TTM)
-0.48
Vốn hóa thị trường
$6.1B
MIRM là gì?
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 369 full-time employees. The company went IPO on 2019-07-18. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). Its clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Livmarli is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with ALGS in the United States and other countries.
